AAV-based gene therapies for neovascular AMD

Area of Science:

• Ophthalmology
• Gene Therapy
• Molecular Biology

Background:

• Neovascular age-related macular degeneration (nAMD) causes irreversible vision loss in the elderly.
• Choroidal neovascularization and vascular endothelial growth factor (VEGF) signaling drive nAMD.
• Current anti-VEGF injections require frequent administration, burdening patients and reducing adherence.

Purpose of the Study:

• To review the rationale and advancements of adeno-associated virus (AAV)-based gene therapy for nAMD.
• To compare ocular gene therapy delivery routes.
• To highlight key clinical candidates and challenges in AAV gene therapy for nAMD.

Main Methods:

• Review of current literature on AAV gene therapy for ocular diseases.
• Comparison of different AAV vector delivery methods within the eye.
• Analysis of clinical trial data and preclinical findings for leading nAMD gene therapy candidates.

Main Results:

• AAV gene therapy enables sustained intraocular delivery of anti-angiogenic agents.
• Several clinical candidates (RGX-314, ADVM-022, 4D-150, NG101) show promise.
• Advances in vector engineering and immune modulation are crucial for efficacy.

Conclusions:

• AAV gene therapy presents a potentially transformative, single-treatment strategy for nAMD.
• Overcoming challenges like pre-existing immunity and inflammation is key for future success.
• Next-generation therapies and precision medicine will refine AAV gene therapy for nAMD.